98%
921
2 minutes
20
Unlabelled: Purpose/Objective(s): To establish a dose-volume response relationship for brain metastases treated with single-fraction robotic stereotactic radiosurgery and identify predictors of local control.
Materials/methods: We reviewed a prospective institutional database of all patients treated for intact brain metastases with stereotactic radiosurgery alone using the CyberKnife robotic radiosurgery system from 2012 to 2015. Tumor response was determined based on Response Evaluation Criteria In Solid Tumors version 1.1. Survival was estimated using the Kaplan-Meier method. Logistic regression modeling was used to identify predictors of outcome and establish a dose-volume response relationship. Receiver operating characteristic curves were constructed to evaluate the predictive capability of the relationship.
Results: There were 357 metastases evaluated in 111 patients with a median diameter of 8.14 mm (2.00-40.77 mm). At 6 and 12 months, local control was 86.9% and 82.2%, respectively. For lesions of similar volumes, higher maximum dose, mean dose, and minimum dose (all P values <.05) predicted for better local control. Tumor volume and diameter were strongly correlated, and a dose-volume response relationship was constructed using mean dose per lesion diameter (Gy/mm) that was predictive of local control (odds ratio: 1.34, 95% confidence interval: 1.06-1.70). Area under the receiver operating characteristic curve for local control and mean dose by volume was 0.6199 with a threshold of 2.05 Gy/mm (local failure 7.6% above and 17.3% below 2.05 Gy/mm).
Conclusion: A dose-volume response relationship exists for brain metastases treated with robotic stereotactic radiosurgery. Mean dose per volume is strongly predictive of local control and can be potentially useful during stereotactic radiosurgery plan evaluation while respecting previously established dose constraints.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616050 | PMC |
http://dx.doi.org/10.1177/1533034616685025 | DOI Listing |
BMC Cancer
September 2025
Department of Oncology, School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Background: Radiotherapy (RT) remains a cornerstone in the treatment of thoracic malignancies; however, approximately one-third of patients with non-small cell lung cancer (NSCLC) develop Grade ≥ 2 radiation-induced lung injury (RILI). Despite its clinical significance, no pharmacologic standard of care has been established for RILI. Pirfenidone, an antifibrotic agent with anti-inflammatory and antioxidant properties, has demonstrated potential in preclinical models of RILI.
View Article and Find Full Text PDFArXiv
August 2025
Department of Physics, The University of Texas at Arlington, Arlington, TX, United States.
Objective: This study aims to uncover the opaque decision-making process of an artificial intelligence (AI) agent for automatic treatment planning.
Approach: We examined a previously developed AI agent based on the Actor-Critic with Experience Replay (ACER) network, which automatically tunes treatment planning parameters (TPPs) for inverse planning in prostate cancer intensity modulated radiotherapy. We selected multiple checkpoint ACER agents from different stages of training and applied an explainable AI (EXAI) method to analyze the attribution from dose-volume histogram (DVH) inputs to TPP-tuning decisions.
Med Phys
September 2025
Division of Applied Quantum Science and Engineering, Faculty of Engineering, Hokkaido University, Sapporo, Hokkaido, Japan.
Background: Tracking irradiation to moving targets in spot-scanning particle therapy, which corrects the spot position and energy in real-time, may decrease treatment time and increase accuracy. However, because of the temporal performance of the system, clinical translation remains challenging. Processing time, including image acquisition, volumetric image synthesis, correction assessment, and system response, is required to control the actual treatment system.
View Article and Find Full Text PDFJ Radiat Res
August 2025
Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
In recurrent gynecologic malignancies following prior pelvic irradiation, definitive radiation therapy is often precluded by cumulative dose constraints to adjacent organs at risk (OARs), and patients may be left with only highly invasive surgical options such as total pelvic exenteration. While some institutions have explored displacement techniques such as artificial ascites or hyaluronic acid gel injection, these approaches are not widely adopted and frequently fail to ensure consistent and stable separation of OARs. We report the first clinical use of Neskeep®, a bioabsorbable polyglycolic acid (PGA) spacer, in high-dose-rate (HDR) brachytherapy for recurrent cervical cancer after prior pelvic radiation.
View Article and Find Full Text PDFClin Transl Radiat Oncol
September 2025
Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India.
We thank the authors for their insightful commentary on our manuscript, "Acute Enteritis with Pelvic SBRT: Influence of Bowel Delineation Methods." In this response, we clarify our methodological decision to focus exclusively on acute enteritis and to exclude proctitis. We highlight the distinct clinical profiles of proctitis and enteritis, emphasizing the importance of careful history taking and clinical evaluation.
View Article and Find Full Text PDF